Increasing Demand of Smart Inhalers Market by 2026 | Novartis AG, BoehringerIngelheim International GmbH, Teva Pharmaceutical Industries
iCrowd Newswire
06 May 2021, 18:25 GMT+10
The drugs used in the inhalers include anti-cholinergic, glucocorticoids, insulin, and beta-agonists for the treatment and prevention of respiratory diseases such as asthma and chronic obstructive pulmonary diseases. These inhalers are termed smart inhalers, owing to the sensors attached as a clip on to the inhalers monitoring the right dose per intake and the technique used for inhaling the medication. The data acquired by the sensor is shared with the patient and healthcare professionals to track their inhaler usage
The market growth of smart inhalers can be attributed to factors such as the growing geriatric population globally and the rising number of patients suffering from respiratory diseases. According to the Office of Disease Prevention and Health Promotion, more than 25 million in the U.S. are suffering from asthma and 14.8 million adults have been diagnosed with COPD. Also, according to the WHO, smoking is considered to be a primary cause for COPD and more than 1 billion people inhale polluted air exposed to tobacco outdoors. These are among the primary factors that will lead to market growth.